| Jul 23 |
Jaguar Health shares slump following Phase III Mytesi failure
|
| Jul 23 |
Crude Oil Down 2%; GE Aerospace Earnings Top Views
|
| Jul 23 |
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
|
| Jul 23 |
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
|
| Jul 18 |
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
|
| Jun 26 |
Jaguar Health regains compliance with Nasdaq's listing rule
|
| Jun 26 |
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
|
| Jun 21 |
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
|
| Jun 12 |
Jaguar Health slips after update on anti-diarrheal therapy
|
| Jun 12 |
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
|
